

# Waaree Energies

|                 |   |
|-----------------|---|
| Estimate change | ↔ |
| TP change       | ↔ |
| Rating change   | ↔ |

| Bloomberg             | WAAREEN IN  |
|-----------------------|-------------|
| Equity Shares (m)     | 288         |
| M.Cap.(INRb)/(USDb)   | 759.9 / 8.3 |
| 52-Week Range (INR)   | 3865 / 1809 |
| 1, 6, 12 Rel. Per (%) | -10/-16/0   |
| 12M Avg Val (INR M)   | 6523        |

## Financials Snapshot (INR b)

| Y/E March         | FY26E | FY27E | FY28E |
|-------------------|-------|-------|-------|
| Sales             | 250.3 | 340.5 | 387.9 |
| Sales Gr. %       | 73.3  | 36.0  | 13.9  |
| EBITDA            | 58.6  | 72.5  | 79.5  |
| EBITDA margin %   | 23.4  | 21.3  | 20.5  |
| Adj. PAT          | 38.7  | 46.2  | 50.1  |
| EPS (INR)         | 134.7 | 160.9 | 174.4 |
| EPS Gr. (%)       | 106.8 | 19.5  | 8.4   |
| BV/Sh. (INR)      | 447.8 | 599.3 | 762.9 |
| <b>Ratios</b>     |       |       |       |
| ND/Equity         | (0.4) | (0.0) | (0.0) |
| ND/EBITDA         | (0.8) | (0.0) | (0.1) |
| RoE (%)           | 34.6  | 30.7  | 25.6  |
| RoIC (%)          | 134.4 | 57.3  | 35.3  |
| <b>Valuations</b> |       |       |       |
| P/E (x)           | 19.6  | 16.4  | 15.1  |
| EV/EBITDA (x)     | 12.1  | 10.5  | 9.5   |

## Shareholding Pattern (%)

| As On    | Dec-25 | Sep-25 | Dec-24 |
|----------|--------|--------|--------|
| Promoter | 64.2   | 64.2   | 64.3   |
| DII      | 2.9    | 2.8    | 2.7    |
| FII      | 6.9    | 6.4    | 1.4    |
| Others   | 26.0   | 26.6   | 31.6   |

CMP: INR2,642

TP: INR3,514 (+33%)

Buy

## Record orderbook underpins earnings visibility

- Waaree Energies (WEL) reported a strong 3QFY26 performance, with revenue of INR75.7b, 16% ahead of our estimates, and EBITDA beating estimates by 26%, driven by a higher-than-anticipated EBITDA margin of 25%. The margin outperformance reflects improved operational efficiency and a favorable product mix. Module/cell production improved 34%/35% QoQ.
- Notable positives from the results: 1) The company remains on track to exceed its FY26 EBITDA guidance of INR55b–INR60b, 2) Looking ahead, we expect limited downside risk to margins, as the increasing share of DCR modules in overall sales (cell production was up 35% QoQ) is enhancing realizations, 3) While silver price volatility remains a concern, silver constitutes less than 9% of total module cost, and its impact is being mitigated through pre-tied contracts, higher utilization, and improved cost absorption, 4) Additionally, the removal of China's export rebates has pushed Chinese cell prices from ~4 cents/Wp to ~6 cents/Wp, narrowing the cost gap and improving the global competitiveness of Indian manufacturers such as WEL.
- Key investor concerns: 1) volatility in silver prices, a slowdown in tendering activity for pure-play solar and hybrid/FDRE projects in FY26 YTD, and 2) the relatively lower domestic share of ~35% in WEL's order book.
- Valuation and view: Our estimates build in a margin of safety, factoring in a gradual EBITDA margin moderation from 23.5% in FY26 to 20.5% by FY28. At 9.5x FY28 EV/EBITDA, WEL continues to trade at an attractive valuation. We value the domestic module business at 13x FY28E EBITDA, the US module business at 12x FY28E EBITDA (in line with global peers), and the new business segment at 10x FY28E EBITDA. The sum of these segment valuations (adjusting for net debt) results in a TP of INR3,514/share.
- Reiterate BUY with a TP of INR3,514.

## Beat on revenue; robust EBITDA margin

### Financial Highlights

- WEL reported consol. revenue of INR75.7b (+119% YoY, +25% QoQ), beating our estimates by 16%.
- EBITDA came in at INR19.3b, up 167% YoY and 37% QoQ, beating our estimate by 26% on account of higher-than-expected EBITDA margin of 25%.
- Adj PAT was 24% higher than est. at INR12.8b (+161% YoY, +52% QoQ).
- WEL recorded an exceptional expense of INR2.9b related to a provision for liabilities arising from the ongoing investigation by the US CBP.

### Operational Highlights

- Module production stood at 3.51GW for 3QFY26, improving 34% QoQ, while cell production for the quarter stood at 0.75GW, up 35% QoQ.
- During 3QFY26, WEL added 5.1GW of module capacity and 3GW of its pilot solar inverter facility.

- Order book stood at INR600b as of 21<sup>st</sup> Jan'26, with 35% domestic and 65% overseas orders.
- WEL's installed module/cell capacity stood at 22.8/5.4GW as of end 3QFY26.

### Highlights of 3QFY26 performance

- WEL produced a record 3.51GW of solar modules in 3QFY26, up 34% QoQ, including 275MW from its US facility, and added 5.1GW of fresh module capacity during the quarter.
- Cell production rose 35% QoQ to 0.75GW, with total installed capacity reaching 22.8GW for modules and 5.4GW for cells.
- During 9MFY26, the company reported revenue of INR180.6b and EBITDA of INR43.3b, translating into an EBITDA margin of ~24%, a sharp improvement from ~17% in 9MFY25.
- Order book stood at INR600b as of 21<sup>st</sup> Jan'26, with 35% domestic and 65% overseas orders; 80–85% of domestic orders are non-DCR.
- Management is confident of surpassing FY26 EBITDA guidance of INR55-60b.
- WEL raised INR10b equity for a 20GWh lithium-ion cell and battery plant; 3.5GWh is expected to be operational by FY27.
- WEL secured a non-Chinese polysilicon supply via a USD30m investment in United Solar Holding (Oman); production is expected from 4QFY26.
- “Waaree 2.0” aims to transform into an integrated clean-energy platform, building renewable infrastructure assets alongside module, BESS, inverter, transformer, and electrolyser manufacturing.

### Valuation and view

- The valuation of WEL has been derived through a sum-of-the-parts (SoTP) methodology, resulting in a TP of INR3,514/share.
- The domestic module business is valued at 13x FY28E EBITDA. The US module business is valued at 12x FY28E EBITDA, which is in line with global peers. The new business segment, valued at 10x FY28E EBITDA, is consistent with domestic peer valuations. The sum of these segment valuations (adjusting for net debt) results in a TP of INR3,514/share.

| Y/E March                    | Consolidated performance |               |               |               |               |               |               |               | (INR m)        |                |               |           |            |           |
|------------------------------|--------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|----------------|----------------|---------------|-----------|------------|-----------|
|                              | FY25                     |               |               |               | FY26E         |               |               |               | FY25           |                | FY26E         | FY26      | Var.       | YoY       |
|                              | 1Q                       | 2Q            | 3Q            | 4Q            | 1Q            | 2Q            | 3Q            | 4QE           |                | 3QE            | (%)           | (%)       | (%)        | (%)       |
| <b>Net Sales</b>             | <b>34,089</b>            | <b>35,744</b> | <b>34,573</b> | <b>40,039</b> | <b>44,258</b> | <b>60,656</b> | <b>75,651</b> | <b>69,727</b> | <b>144,445</b> | <b>250,292</b> | <b>65,488</b> | <b>16</b> | <b>119</b> | <b>25</b> |
| YoY Change (%)               | 2%                       | 1%            | 117%          | 36%           | 30%           | 70%           | 119%          | 74%           | 27%            | 73%            | 89%           |           |            |           |
| Total Expenditure            | 28,564                   | 30,495        | 27,356        | 30,814        | 34,285        | 46,592        | 56,369        | 54,477        | 117,229        | 191,723        | 50,157        | <b>12</b> | <b>106</b> | <b>21</b> |
| <b>EBITDA</b>                | <b>5,525</b>             | <b>5,249</b>  | <b>7,217</b>  | <b>9,226</b>  | <b>9,973</b>  | <b>14,064</b> | <b>19,282</b> | <b>15,250</b> | <b>27,216</b>  | <b>58,569</b>  | <b>15,331</b> | <b>26</b> | <b>167</b> | <b>37</b> |
| Margin (%)                   | 16%                      | 15%           | 21%           | 23%           | 23%           | 23%           | 25%           | 22%           | 19%            | 23%            | 23%           |           |            |           |
| Depreciation                 | 758                      | 843           | 891           | 1,534         | 1,821         | 2,398         | 2,673         | 2,724         | 4,025          | 9,615          | 2,463         | 8         | 200        | 11        |
| Interest                     | 337                      | 308           | 309           | 567           | 433           | 961           | 933           | 908           | 1,521          | 3,234          | 714           | 31        | 202        | -3        |
| Other Income                 | 875                      | 891           | 880           | 1,370         | 1,714         | 1,609         | 1,962         | 1,849         | 4,016          | 7,133          | 1,790         | 10        | 123        | 22        |
| <b>PBT before EO expense</b> | <b>5,305</b>             | <b>4,988</b>  | <b>6,898</b>  | <b>8,495</b>  | <b>9,434</b>  | <b>12,315</b> | <b>17,638</b> | <b>13,467</b> | <b>25,687</b>  | <b>52,854</b>  | <b>13,944</b> |           |            |           |
| Extra-Ord income/(exp.)      | 0                        | 0             | 0             | -40           | 0             | 0             | -2,948        | 0             | -40            | -2,948         | 0             |           |            |           |
| <b>PBT</b>                   | <b>5,305</b>             | <b>4,988</b>  | <b>6,898</b>  | <b>8,455</b>  | <b>9,434</b>  | <b>12,315</b> | <b>14,690</b> | <b>13,467</b> | <b>25,646</b>  | <b>49,906</b>  | <b>13,944</b> | <b>5</b>  | <b>113</b> | <b>19</b> |
| Tax                          | 1,294                    | 1,232         | 1,829         | 2,010         | 1,705         | 3,533         | 3,622         | 3,118         | 6,365          | 11,977         | 3,346         |           |            |           |
| Rate (%)                     | 24%                      | 25%           | 27%           | 24%           | 18%           | 29%           | 25%           | 23%           | 25%            | 24%            | 24%           |           |            |           |
| Share of JV & associates     | 0                        | 0             | 0             | 0             | 0             | 0             | 0             | 0             | 0              | 0              | 0             |           |            |           |
| Minority Interest            | 70                       | 140           | 142           | 256           | 277           | 357           | 443           | 387           | 607            | 1,463          | 232           |           |            |           |
| <b>Reported PAT</b>          | <b>3,941</b>             | <b>3,617</b>  | <b>4,927</b>  | <b>6,189</b>  | <b>7,452</b>  | <b>8,426</b>  | <b>10,625</b> | <b>9,963</b>  | <b>18,674</b>  | <b>36,465</b>  | <b>10,597</b> | <b>0</b>  | <b>116</b> | <b>26</b> |
| <b>Adj PAT</b>               | <b>3,941</b>             | <b>3,617</b>  | <b>4,927</b>  | <b>6,220</b>  | <b>7,452</b>  | <b>8,426</b>  | <b>12,846</b> | <b>9,963</b>  | <b>18,704</b>  | <b>38,686</b>  | <b>10,366</b> | <b>24</b> | <b>161</b> | <b>52</b> |
| YoY Change (%)               | 17%                      | 15%           | 467%          | 148%          | 89%           | 133%          | 161%          | 60%           | 90%            | 107%           | 110%          |           |            |           |
| Margin (%)                   | 11.6                     | 10.1          | 14.3          | 15.5          | 16.8          | 13.9          | 17.0          | 14.3          | 12.9           | 15.5           | 15.8          |           |            |           |

**Exhibit 1: Valuation Summary**

| Sum of the parts valuation | Unit         | FY28   | Multiple | EV           | Comments                    |
|----------------------------|--------------|--------|----------|--------------|-----------------------------|
| Domestic Modules           | INR b        | EBITDA | 49       | 13           | 662                         |
| USA Modules                | INR b        | EBITDA | 18       | 12           | 220                         |
| New businesses             | INR b        | EBITDA | 12       | 10           | In line with domestic peers |
| <b>Total EV</b>            | <b>INR b</b> |        |          | <b>1,010</b> |                             |
| Less: Minority Interest    | INR b        |        |          | 6            |                             |
| Less: Net debt             | INR b        |        |          | -6           |                             |
| <b>Market Cap</b>          | <b>INR b</b> |        |          | <b>1,009</b> |                             |
| NOSH                       | m            |        |          | 287          |                             |
| <b>Target price</b>        | <b>INR</b>   |        |          | <b>3,514</b> |                             |
| CMP                        | INR          |        |          | 2,642        |                             |
| <b>Upside / (Downside)</b> | <b>%</b>     |        |          | <b>33%</b>   |                             |

Source: Company, MOFSL


**Highlights from the management commentary**

- **Manufacturing scale-up, capacity additions, and order book strength**
  - Module production stood at 3.51GW for the quarter, improving 34% QoQ, which included 275MW produced in the US facility.
  - Cell production during the quarter stood at 0.75GW, registering a growth of 35% QoQ. It consumes nearly all the cells that it produces internally.
  - The total installed capacity reached 22.8GW for modules and 5.4GW for cells as of 3QFY26 end.
  - During the quarter, WEL added 5.1GW of module capacity and a 3GW pilot inverter facility.
  - Cell utilization during 3QFY26 was ~56%. Management claims that the current utilization has improved to 80–81% and can further improve to 85-90% in the next 3-4 months with a shift to standardized G-12R cells.
  - WEL's order book stood at INR600b as of 21 Jan'26, with 35% domestic and 65% overseas orders. Within the domestic share, ~80–85% is currently non-DCR.
- **Financial metrics:**
  - WEL reported consolidated revenue of INR75.7b in 3QFY26, up 118% YoY, driven by strong module volume growth.
  - Operating EBITDA for the quarter stood at INR19.3b, an increase of 167% YoY.
  - During 9M FY26, the company reported revenue of INR180.6b and EBITDA of INR43.3b, translating into an EBITDA margin of ~24%, a sharp improvement from ~17% in 9MFY25.
  - Management is confident of surpassing its FY26 EBITDA guidance of INR55-60b.
  - Overseas revenue (excl. inter-segment eliminations) exceeded INR20b in 3QFY26.
  - An exceptional expense of INR2.9b was recorded toward a provision made for potential liabilities related to the ongoing investigation under US Customs and Border Protection. No demand has yet been raised, but the company recognized the provision after consultation with legal advisors in the US.
- **Diversified expansion across renewables, batteries, and upstream integration**
  - Alongside manufacturing expansion, the company is developing renewable infrastructure, with PPAs signed for 713 MW (AC)/1,069 MWp (DC), connectivity secured for ~6.1GW, and a committed capex of over INR22.5b to build, de-risk,

and subsequently monetize part of the portfolio with marquee C&I customers, utilities, and global renewable investors.

- WEL has also raised INR10b equity for its 20GWh lithium-ion cell and battery manufacturing plant, as part of the announced capex of INR100b. Of the 20GWh, 3.5GWh will come by FY27 itself, with the balance coming in FY28. We expect the company to venture into the export market for batteries, as the cost of batteries is ~USD70-80/kWh in India and 40-50% higher in the US.
- WEL has secured a non-Chinese polysilicon supply chain through a USD30m strategic investment in United Solar Holding of Oman, and production is expected as early as 4QFY26.
- WEL has also commissioned 1GW of solar inverter facility in 3QFY26, with an additional gigawatt of capacity coming in FY27.
- **US market opportunity and IRA-led profitability tailwinds**
- The US continues to be one of the key growth markets for WEL, supported by IRA benefits and a rapidly expanding demand.
- The company's US facility contributed 275MW of module production in 3QFY26.
- The country of origin for exports is determined by cell manufacturing location, allowing tariff optimization through strategic sourcing.
- Management stated that the US remains a structurally important and profitable geography for WEL, especially after the recent rise in Chinese cell prices following the removal of export rebates.
- WEL booked IRA incentive income of INR0.8b during the quarter. IRA generally provides 7 cents/Wp of incentive, and WEL realized around 90% of that rate.
- **Margin drivers and cost competitiveness in solar manufacturing**
- WEL highlighted that silver accounts for less than 9% of total module cost, and rising input prices are being offset by means of pre-tied contracts, improving operating leverage.
- The increase in the share of DCR modules in the organization's sales has led to better realizations, thereby boosting margins.
- Cell production cost in India currently stands around 7 cents/Wp, with silver contributing about 25% of total cell cost.
- DCR realizations are around INR23/Wp, while non-DCR realizations in India are INR14–15/Wp and about INR23/Wp in the US domestic market.
- The company noted that cell and module production improvements, coupled with higher utilization and DCR share, will enhance cost absorption and maintain profitability.
- China's export rebate removal has lifted Chinese cell prices from 4 cents/Wp to 6 cents/Wp, narrowing the cost differential and improving India's global competitiveness.


## Story in charts – 3QFY26

### Exhibit 1: Operational Snapshot

| Particulars                 | 2QFY25      | 3QFY25      | 4QFY25      | 1QFY26      | 2QFY26      | 3QFY26      |
|-----------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| <b>Module Capacity (GW)</b> | <b>13.3</b> | <b>14.9</b> | <b>14.9</b> | <b>14.9</b> | <b>18.7</b> | <b>22.8</b> |
| Domestic                    | 13.3        | 13.3        | 13.3        | 13.3        | 16.1        | 21.2        |
| US                          | 0           | 1.6         | 1.6         | 1.6         | 2.6         | 1.6         |
| <b>Cell Capacity (GW)</b>   | <b>0</b>    | <b>5.4</b>  | <b>5.4</b>  | <b>5.4</b>  | <b>5.4</b>  | <b>5.4</b>  |
| Module Production (GW)      | 1.9         | 3.17        | N.A.        | 2.3         | 2.6         | 3.51        |
| Cell Production (GW)        |             |             |             |             | 0.6         | 0.8         |
| <b>Order Book (INRb)</b>    | <b>NA</b>   | <b>500</b>  | <b>470</b>  | <b>490</b>  | <b>470</b>  | <b>600</b>  |


Source: Company, MOFSL

### Exhibit 2: Revenue and EBITDA (INRb)




Source: Company, MOFSL

### Exhibit 3: EBITDA margin (%)




Source: Company, MOFSL

### Exhibit 4: Quarterly revenue and APAT (INRb)




Source: Company, MOFSL

### Exhibit 5: Quarterly EBITDA (INRb) and EBITDA margin (%)




Source: Company, MOFSL

**Exhibit 6: Revenue split for 3QFY26**



Source: Company, MOFSL

**Exhibit 7: Annual trends in RoE and RoCE (%)**



Source: Company, MOFSL

## Financials and valuations

### Consolidated Income Statement

|  | INR m         |                |                |                |                |                |
|--|---------------|----------------|----------------|----------------|----------------|----------------|
| Y/E March                                      | FY23          | FY24           | FY25           | FY26E          | FY27E          | FY28E          |
| <b>Net Sales</b>                               | <b>67,509</b> | <b>113,976</b> | <b>144,445</b> | <b>250,292</b> | <b>340,484</b> | <b>387,929</b> |
| Change (%)                                     | 137%          | 69%            | 27%            | 73%            | 36%            | 14%            |
| Total Expenses                                 | 59,162        | 98,232         | 117,229        | 191,723        | 267,936        | 308,433        |
| Gross Profit                                   | 14,345        | 23,838         | 39,237         | 76,282         | 91,147         | 99,025         |
| <b>EBITDA</b>                                  | <b>8,346</b>  | <b>15,744</b>  | <b>27,216</b>  | <b>58,569</b>  | <b>72,548</b>  | <b>79,496</b>  |
| EBITDAM (%)                                    | 12%           | 14%            | 19%            | 23%            | 21%            | 20%            |
| Depn. & Amortization                           | 1,641         | 2,768          | 4,025          | 9,615          | 14,397         | 15,827         |
| <b>EBIT</b>                                    | <b>6,705</b>  | <b>12,976</b>  | <b>23,192</b>  | <b>48,954</b>  | <b>58,151</b>  | <b>63,669</b>  |
| Net Interest and finance cost                  | 823           | 1,399          | 1,521          | 3,234          | 4,924          | 5,492          |
| Other income                                   | 1,095         | 2,352          | 4,016          | 7,133          | 9,204          | 8,998          |
| <b>PBT before extraordinary items</b>          | <b>6,977</b>  | <b>13,929</b>  | <b>25,687</b>  | <b>52,854</b>  | <b>62,430</b>  | <b>67,176</b>  |
| EO income/ (expense)                           | (206)         | 3,413          | (40)           | (2,948)        | -              | -              |
| <b>PBT</b>                                     | <b>6,772</b>  | <b>17,342</b>  | <b>25,646</b>  | <b>49,906</b>  | <b>62,430</b>  | <b>67,176</b>  |
| Tax  | 1,769         | 4,598          | 6,365          | 11,977         | 14,671         | 15,114         |
| Rate (%)                                       | 26%           | 27%            | 25%            | 24%            | 23%            | 23%            |
| JV/Associates                                  | -             | -              | -              | -              | -              | -              |
| <b>Profit from continued operations</b>        | <b>5,003</b>  | <b>12,744</b>  | <b>19,281</b>  | <b>37,928</b>  | <b>47,760</b>  | <b>52,061</b>  |
| Profit from Discontinued Operations before tax | -             | -              | -              | -              | -              | -              |
| Tax (Discontinued operations)                  | -             | -              | -              | -              | -              | -              |
| <b>Reported PAT</b>                            | <b>4,828</b>  | <b>12,372</b>  | <b>18,674</b>  | <b>36,465</b>  | <b>46,220</b>  | <b>50,095</b>  |
| Minority                                       | 175           | 372            | 607            | 1,463          | 1,540          | 1,966          |
| <b>Adjusted PAT</b>                            | <b>4,980</b>  | <b>9,863</b>   | <b>18,704</b>  | <b>38,686</b>  | <b>46,220</b>  | <b>50,095</b>  |
| YoY change (%)                                 | 558%          | 98%            | 90%            | 107%           | 19%            | 8%             |

### Consolidated Balance Sheet

|                                    | INR m         |               |                |                |                |                |
|------------------------------------|---------------|---------------|----------------|----------------|----------------|----------------|
| As on Y/E March                    | FY23          | FY24          | FY25           | FY26E          | FY27E          | FY28E          |
| Share Capital                      | 2,434         | 2,630         | 2,873          | 2,876          | 2,876          | 2,876          |
| Reserves                           | 15,950        | 38,249        | 91,919         | 125,770        | 169,299        | 216,277        |
| <b>Net Worth</b>                   | <b>18,384</b> | <b>40,878</b> | <b>94,792</b>  | <b>128,647</b> | <b>172,176</b> | <b>219,153</b> |
| Minority Interest                  | 234           | 607           | 1,161          | 2,624          | 4,164          | 6,131          |
| Total Loans                        | 2,735         | 3,173         | 9,395          | 21,895         | 56,895         | 65,145         |
| <b>Capital Employed</b>            | <b>21,353</b> | <b>44,658</b> | <b>105,347</b> | <b>153,166</b> | <b>233,235</b> | <b>290,429</b> |
| <b>Net Fixed Assets</b>            | <b>10,986</b> | <b>14,432</b> | <b>40,292</b>  | <b>65,097</b>  | <b>117,910</b> | <b>176,630</b> |
| Capital WIP                        | 5,372         | 13,414        | 18,841         | 34,421         | 67,211         | 47,664         |
| Goodwill                           | 63            | 63            | 63             | 63             | 63             | 63             |
| Investments                        | 314           | 715           | 801            | 801            | 801            | 801            |
| <b>Curr. Assets</b>                | <b>57,464</b> | <b>84,513</b> | <b>137,476</b> | <b>160,499</b> | <b>171,476</b> | <b>198,169</b> |
| Inventories                        | 27,089        | 25,855        | 26,921         | 48,001         | 65,298         | 74,397         |
| Account Receivables                | 3,126         | 9,714         | 11,848         | 20,572         | 27,985         | 31,885         |
| Cash and Cash Equivalents          | 17,364        | 37,792        | 77,478         | 70,697         | 56,963         | 70,658         |
| Others                             | 9,885         | 11,152        | 21,229         | 21,229         | 21,229         | 21,229         |
| <b>Curr. Liability &amp; Prov.</b> | <b>52,846</b> | <b>68,479</b> | <b>92,126</b>  | <b>107,716</b> | <b>124,227</b> | <b>132,899</b> |
| Account Payables                   | 14,316        | 14,752        | 22,549         | 38,139         | 54,649         | 63,322         |
| Provisions & Others                | 38,530        | 53,727        | 69,577         | 69,577         | 69,577         | 69,577         |
| <b>Net Curr. Assets</b>            | <b>4,618</b>  | <b>16,034</b> | <b>45,350</b>  | <b>52,783</b>  | <b>47,249</b>  | <b>65,270</b>  |
| <b>Appl. of Funds</b>              | <b>21,353</b> | <b>44,658</b> | <b>105,347</b> | <b>153,166</b> | <b>233,235</b> | <b>290,429</b> |

## Financials and valuations

### Ratios

| Particulars                   | FY23   | FY24  | FY25  | FY26E | FY27E | FY28E |
|-------------------------------|--------|-------|-------|-------|-------|-------|
| <b>Basic (INR)</b>            |        |       |       |       |       |       |
| EPS                           | 20.5   | 37.5  | 65.1  | 134.7 | 160.9 | 174.4 |
| Cash EPS                      | 27.2   | 48.0  | 79.1  | 168.1 | 211.0 | 229.5 |
| BV/Share                      | 75.5   | 155.5 | 330.0 | 447.8 | 599.3 | 762.9 |
| DPS                           | 0.0    | 0.0   | 0.0   | 4.0   | 4.0   | 4.0   |
| Payout (%)                    | 0.1    | 0.1   | 0.0   | 3.0   | 2.5   | 2.3   |
| Dividend yield (%)            | 0.0    | 0.0   | 0.0   | 0.1   | 0.1   | 0.1   |
| <b>Valuation (x)</b>          |        |       |       |       |       |       |
| P/E                           | 129.1  | 70.4  | 40.6  | 19.6  | 16.4  | 15.1  |
| Cash P/E                      | 97.1   | 55.0  | 33.4  | 15.7  | 12.5  | 11.5  |
| P/BV                          | 35.0   | 17.0  | 8.0   | 5.9   | 4.4   | 3.5   |
| EV/EBITDA                     | 75.3   | 41.9  | 25.4  | 12.1  | 10.5  | 9.5   |
| <b>Return Ratios (%)</b>      |        |       |       |       |       |       |
| RoE                           | 44%    | 33%   | 28%   | 35%   | 31%   | 26%   |
| RoCE (post-tax)               | 40%    | 34%   | 27%   | 33%   | 27%   | 22%   |
| RoIC (post-tax)               | -1571% | -210% | 4166% | 134%  | 57%   | 35%   |
| <b>Working Capital Ratios</b> |        |       |       |       |       |       |
| Fixed Asset Turnover (x)      | 6.1    | 7.9   | 3.6   | 3.8   | 2.9   | 2.2   |
| Asset Turnover (x)            | 3.2    | 2.6   | 1.4   | 1.6   | 1.5   | 1.3   |
| Debtor (Days)                 | 17     | 31    | 30    | 30    | 30    | 30    |
| Inventory (Days)              | 146    | 83    | 68    | 70    | 70    | 70    |
| Payable (Days)                | 98     | 60    | 78    | 80    | 80    | 80    |
| Working Capital (Days)        | 65     | 54    | 20    | 20    | 20    | 20    |
| <b>Leverage Ratio (x)</b>     |        |       |       |       |       |       |
| Net Debt/Equity               | (0.8)  | (0.8) | (0.7) | (0.4) | (0.0) | (0.0) |
| Net Debt/EBITDA               | (1.8)  | (2.2) | (2.5) | (0.8) | (0.0) | (0.1) |

### Consolidated Cash Flow Statement

| Particulars                                  | FY23           | FY24           | FY25           | FY26E          | FY27E          | INR m FY28E    |
|--|----------------|----------------|----------------|----------------|----------------|----------------|
| <b>Profit/(loss) for the year before tax</b> | <b>6,772</b>   | <b>17,342</b>  | <b>25,646</b>  | <b>49,906</b>  | <b>62,430</b>  | <b>67,176</b>  |
| WC   | 7,196          | 5,916          | 11,574         | (14,214)       | (8,200)        | (4,326)        |
| Others                                       | 2,638          | 3,143          | 1,790          | 4,252          | 8,578          | 10,354         |
| Direct taxes (net)                           | (1,004)        | (3,351)        | (7,428)        | (11,977)       | (14,671)       | (15,114)       |
| <b>CF from Op. Activity</b>                  | <b>15,602</b>  | <b>23,050</b>  | <b>31,582</b>  | <b>27,966</b>  | <b>48,137</b>  | <b>58,089</b>  |
| Capex  | (8,618)        | (13,374)       | (32,456)       | (50,000)       | (100,000)      | (55,000)       |
| <b>FCFF</b>                                  | <b>6,984</b>   | <b>9,677</b>   | <b>-874</b>    | <b>-22,034</b> | <b>-51,863</b> | <b>3,089</b>   |
| Interest income                              | 295            | 1,249          | 2,983          | 7,133          | 9,204          | 8,998          |
| Others                                       | (12,616)       | (21,278)       | (38,610)       | -              | -              | -              |
| <b>CF from Inv. Activity</b>                 | <b>-20,938</b> | <b>-33,403</b> | <b>-68,084</b> | <b>-42,867</b> | <b>-90,796</b> | <b>-46,002</b> |
| Share capital                                | 10,194         | 10,035         | 35,080         | 4              | -              | -              |
| Borrowings                                   | (1,508)        | 416            | 6,221          | 12,500         | 35,000         | 8,250          |
| Finance cost                                 | (655)          | (1,207)        | (714)          | (3,234)        | (4,924)        | (5,492)        |
| Dividend                                     | (3)            | (5)            | -              | (1,151)        | (1,151)        | (1,151)        |
| Others                                       | (1,603)        | (147)          | (230)          | -              | -              | -              |
| <b>CF from Fin. Activity</b>                 | <b>6,425</b>   | <b>9,092</b>   | <b>40,357</b>  | <b>8,119</b>   | <b>28,925</b>  | <b>1,608</b>   |
| <b>(Inc)/Dec in Cash</b>                     | <b>1,089</b>   | <b>-1,260</b>  | <b>3,856</b>   | <b>-6,781</b>  | <b>-13,734</b> | <b>13,694</b>  |
| Opening balance                              | 1,392          | 2,537          | 1,214          | 77,478         | 70,697         | 56,963         |
| <b>Closing balance (as per B/S)</b>          | <b>17,364</b>  | <b>37,792</b>  | <b>77,478</b>  | <b>70,697</b>  | <b>56,963</b>  | <b>70,658</b>  |

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

| Explanation of Investment Rating |  |
|----------------------------------|--|
| Investment Rating                | Expected return (over 12-month)  |
| BUY                              | >=15%  |
| SELL                             | < - 10%  |
| NEUTRAL                          | < - 10 % to 15%  |
| UNDER REVIEW                     | Rating may undergo a change  |
| NOT RATED                        | We have forward looking estimates for the stock but we refrain from assigning recommendation |

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein, (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA.

Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

\*\*\*\*\*  
The associates of MOFSL may have:

financial interest in the subject company  
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

#### Grievance Redressal Cell:

| Contact Person     | Contact No.                 | Email ID                     |
|--------------------|-----------------------------|------------------------------|
| Ms. Hemangi Date   | 022 40548000 / 022 67490600 | query@motilaloswal.com       |
| Ms. Kumud Upadhyay | 022 40548082                | servicehead@motilaloswal.com |
| Mr. Ajay Menon     | 022 40548083                | am@motilaloswal.com          |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.